The agents currently approved for the treatment of IBD are infliximab, adalimumab, golimumab and certolizumab pegol as anti-TNF-α agents, natalizumab and vedolizumab as anti-integrin agents, ustekinumab as an anti-IL 12/23 agent [7] and tofacitinib as an anti-JAK agent [8]. Here, TNF is linked to inflammatory bowel disease.